Documents

Explore the latest documents from the company, including regulatory filings and corporate disclosures that offer insight into company performance and strategy. Use these resources to support informed investment decisions.

2026

Earnings, Q2 FY2026

Jul 29, 2026

Q2 revenue up 20% year-over-year; 2026 guidance raised amid strong Rx growth and margin gains.

Earnings, Q1 FY2026

May 6, 2026

Q1 2026 revenue rose 18% to €849M, with margin and Rx growth, but guidance unchanged.

2025

Earnings, Q4 FY2025

Mar 4, 2026

Revenue up 24% to EUR 2.9B, Rx growth leads, 2026 EBITDA margin guidance at 2.5%+.

Earnings, Q3 FY2025

Oct 30, 2025

27% sales growth and strong cash flow support continued investment and market expansion.

Earnings, Q2 FY2025

Jul 29, 2025

Record sales and EBITDA growth, with guidance reaffirmed amid regulatory and digital tailwinds.

Earnings, Q1 FY2025

May 6, 2025

Q1 2025 sales up 28% year-over-year, with RX growth and positive EBITDA; guidance reaffirmed.

2024

Earnings, Q4 FY2024

Mar 11, 2025

2024 saw 32% sales growth, Rx leadership, and strong 2025 guidance amid ongoing investments.

Earnings, Q3 FY2024

Nov 5, 2024

Record sales growth and accelerating eRx adoption drive strong financial performance.

Trading Update

Oct 4, 2024

Raised sales guidance and strong eRx momentum drive continued investment and growth.

Earnings, Q2 FY2024

Jul 30, 2024

Earnings, Q1 FY2024

Apr 25, 2024

2023

Earnings, Q4 FY2023

Mar 5, 2024

Earnings, Q3 FY2023

Oct 31, 2023

Earnings, Q2 FY2023

Aug 1, 2023

Earnings, Q1 FY2023

May 2, 2023

2022

Earnings, Q4 FY2022

Mar 7, 2023

Earnings, Q3 FY2022

Oct 31, 2022

Earnings, Q2 FY2022

Aug 3, 2022

Earnings, Q1 FY2022

May 5, 2022

2021

Earnings, Q4 FY2021

Mar 2, 2022

Earnings, Q3 FY2021

Nov 2, 2021

Earnings, Q2 FY2021

Aug 5, 2021

Guidance

Jul 23, 2021

Earnings, Q1 FY2021

May 6, 2021

Redcare Pharmacy N.V.

Documents